Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, 201508, People's Republic of China.
State Key Laboratory of Metal Matrix Composites, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.
J Nanobiotechnology. 2022 Jul 7;20(1):319. doi: 10.1186/s12951-022-01487-6.
Chemoresistance is often a cause of the failure of chemotherapy in cancer treatment. Sorcin (SRI) is a soluble resistance-related calcium-binding protein involved in chemoresistant processes and is overexpressed in many chemoresistant cancer cells, including paclitaxel (PTX)-resistant ovarian cancer. Increased SRI can reduce the concentration of calcium ions in the cytosol and mitochondria and the decrease of calcium ion concentration prevents the occurrence of apoptosis. Here we examined the SRI expression in multiple cancers using a human TissueArray and found that SRI expression was significantly higher in malignant tumor tissues. Furthermore, SRI was overexpressed, while intracellular calcium concentration was decreased, in chemoresistant cancer cells. To restore intracellular calcium homeostasis and overcome chemoresistance, we developed lipid-coated albumin-PTX nanoparticles loaded with SRI-siRNA (LANP-PTX-siSRI) for PTX and SRI-siRNA co-delivery. LANP-PTX-siSRI had dual-target roles in the regulation of SRI and the delivery of PTX into chemoresistant cells. The LANP-PTX-siSRI inhibited the expression of SRI and enhanced intracellular calcium, leading to the induction of apoptosis and the inhibition of the growth of PTX-resistant cancer cells in vitro and in vivo. In addition, the mechanism study revealed that the overexpression of SRI was associated with an impaired TGF-β signaling pathway. The administration of TGF-β1 inhibited two calcium-binding proteins SRI and S100A14. In conclusion, our data unveil that restoring intracellular calcium ion homeostasis via reducing SRI expression can reverse chemoresistance. Thus, the fabricated LANP-PTX-siSRI has a potentially therapeutical application.
化学耐药性常常是癌症治疗中化疗失败的原因。钙结合蛋白 Sorcin(SRI)是一种可溶性耐药相关蛋白,参与耐药过程,在许多耐药癌细胞中过度表达,包括紫杉醇(PTX)耐药卵巢癌。SRI 的增加可以降低细胞质和线粒体中的钙离子浓度,而钙离子浓度的降低可以防止细胞凋亡的发生。在这里,我们使用人类组织芯片检查了多种癌症中的 SRI 表达,发现 SRI 在恶性肿瘤组织中的表达明显更高。此外,在耐药癌细胞中,SRI 表达上调,而细胞内钙离子浓度降低。为了恢复细胞内钙稳态并克服耐药性,我们开发了负载 SRI-siRNA 的脂质包覆白蛋白-PTX 纳米粒(LANP-PTX-siSRI)用于 PTX 和 SRI-siRNA 的共递送。LANP-PTX-siSRI 在调节 SRI 和将 PTX 递送到耐药细胞方面具有双重作用。LANP-PTX-siSRI 抑制 SRI 的表达并增加细胞内钙,导致体外和体内诱导细胞凋亡和抑制 PTX 耐药癌细胞的生长。此外,机制研究表明,SRI 的过表达与 TGF-β 信号通路受损有关。TGF-β1 的给药抑制了两种钙结合蛋白 SRI 和 S100A14。总之,我们的数据揭示了通过降低 SRI 表达来恢复细胞内钙离子稳态可以逆转耐药性。因此,所制备的 LANP-PTX-siSRI 具有潜在的治疗应用。